Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Sirtris' Series B Gets $27M For Class III HDAC Research

March 8, 2005

By Jennifer Boggs

Neurochem Raising $61M For Alzhemed's Phase III Studies

March 7, 2005

By Jennifer Boggs

Neurochem Raising $61M For Alzhemed's Phase III Studies

March 7, 2005

By Jennifer Boggs

Allos Secures $50M Investment For Efaproxyn Phase III Program

March 4, 2005

By Jennifer Boggs

Allos Secures $50M Investment For Efaproxyn Phase III Program

March 4, 2005

By Jennifer Boggs

Osel Gains Lead Bacteria-Based Product Through Licensing Deal

March 3, 2005

By Jennifer Boggs

Osel Gains Lead Bacteria-Based Product Through Licensing Deal

March 3, 2005

By Jennifer Boggs

Discovery Acquires Biofrontera, Expects To Lose Money In 2005

March 2, 2005

By Jennifer Boggs

Discovery Acquires Biofrontera, Expects To Lose Money In 2005

March 2, 2005

By Jennifer Boggs

Tercica Completes Increlex NDA For IGF-1 Deficient Short Stature

March 1, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...